Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Watch

Bendamustine, Obinutuzumab, and Venetoclax Achieve Responses in CLL

DOI: 10.1158/2159-8290.CD-RW2018-145 Published October 2018
  • Article
  • Info & Metrics
Loading
  • Major finding: Bendamustine followed by obinutuzumab and venetoclax provides clinical benefit without unexpected toxicity.

  • Clinical relevance: This treatment regimen led to responses in 95% of patients with CLL in an open-label phase II trial.

  • Impact: Bendamustine followed by obinutuzumab and venetoclax warrants further investigation for the treatment of CLL.

The antiapoptotic protein BCL2 is upregulated in chronic lymphocytic leukemia (CLL), and the BCL2 inhibitor venetoclax induces apoptosis of CLL cells and has demonstrated clinical activity as a monotherapy in patients with relapsed or refractory CLL. Preclinical data suggested that venetoclax may synergize with the anti-CD20 antibody rituximab, and this was supported by a phase Ib trial in patients with CLL. Cramer and colleagues hypothesized that the more potent anti-CD20 antibody obinutuzumab might further enhance the efficacy of venetoclax. To test this hypothesis, a prospective, open-label, phase II trial evaluated the combination of venetoclax and obinutuzumab after debulking with the chemotherapeutic bendamustine. Overall, 66 patients were enrolled, and 63 were evaluable for efficacy; 34 patients (54%) were treatment naïve and 29 (46%) had relapsed or refractory disease. The primary endpoint was the proportion of patients achieving an overall response. In total, 60 of 63 (95%) evaluable patients responded, including all 34 treatment-naïve patients and 26 of 29 (90%) patients with relapsed or refractory disease. There were 25 complete and 35 partial responses. Further, deep minimal residual disease negativity was observed in the peripheral blood of 55 of 63 (87%) patients. The combination of bendamustine, obinutuzumab, and venetoclax produced no unexpected or cumulative toxicities. However, there were 89 serious adverse events, 69 of which were related to the study treatment. Five patients with relapsed or refractory disease died, and three of the deaths were deemed related to the study treatment. Taken together, the results of this trial indicate that bendamustine followed by obinutuzumab and venetoclax achieves a high response rate in patients with CLL without unexpected toxicity. These findings support further investigation of this combination and follow-up to determine if the remissions are durable after treatment discontinuation.

Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018 Aug 13 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2018 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 8 (10)
October 2018
Volume 8, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Bendamustine, Obinutuzumab, and Venetoclax Achieve Responses in CLL
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Bendamustine, Obinutuzumab, and Venetoclax Achieve Responses in CLL
Cancer Discov October 1 2018 (8) (10) OF1; DOI: 10.1158/2159-8290.CD-RW2018-145

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Bendamustine, Obinutuzumab, and Venetoclax Achieve Responses in CLL
Cancer Discov October 1 2018 (8) (10) OF1; DOI: 10.1158/2159-8290.CD-RW2018-145
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
Show more Research Watch

Clinical Trials

  • The LSD1 Inhibitor Iadademstat Is Active in Acute Myeloid Leukemia
  • Intermittent Inhibition of BRAF plus MEK Is Not Beneficial in Melanoma
  • Anti–PD-1 plus a VEGFR2 Inhibitor Shows Promise in Cervical Cancer
Show more Clinical Trials
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement